WHO COVID-19 Trial drops hydroxychloroquine, HIV combo lopinavir/ritonavir after ‘lack of evidence’ in hospitalised patients

Hydroxychloroquine and lopinavir / ratanavir showed no reduction in mortality in hospitalized patients compared to standard of care.

The World Health Organization has pulled the steroid-running hydroxychloroquine and HIV treatment combination lopinavir / ritonavir from its existing COVID-19 solidity trials following a recommendation from the Steering Committee internationally. The Solidarity Trial, established by the WHO, is working to treat hospitalized patients.

Interim results of the trial led to the committee’s recommendation following increasing evidence comparing hydroxychloroquine and lopinavir / ratanavir with standard treatment care: who said In a press release. The evidence from all trials was reviewed and summarized at the July 1-2 WHO Summit on COVID-19 Research and Innovation, the release added.

The hodroxychloroquine HIV combo lopinavi-ritonavir in the WHO COVID19 trial is abandoned after lack of evidence in hospitalized patients
This Tuesday, April 7, 2020 file photo shows a bottle of hydroxychloroquine tablets in Texas City, Texas. The World Health Organization said on Monday May 25, 2020, that it would temporarily drop hydroxychloroquine from its global study into experimental COVID-19 treatments because its experts needed to review all available evidence. (AP Photo / David J. Phillip, File)

Hydroxychloroquine and lopinavir / ratanavir showed little or no reduction in mortality in hospitalized COVID-19 patients compared to standard of care.

However, some safety information was compiled based on clinical findings in the related discovery trial, which is part of the Solidarity trial. The WHO stated that these would be reported in an upcoming peer-review publication. He said the results of interim solidarity are now being read out for peer review.

This decision applies only to the solidarity test of WHO in hospitalized patients, and its use in other studies for the treatment of non-hospitalized patients, or as a pre- or exposure preventive treatment for COVID-19. Does not dismiss, the release clarified.

Earlier this year in laboratory experiments hydroxychloroquine was shown to be able to block the SARS-CoV-2 virus, which causes COVID-19, but this effect has not been replicated in rigorous trials in people .

Back to top button